PMID- 24281316
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20151119
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 19
IP  - 1
DP  - 2014 Jan
TI  - Pharmacologic therapy for erectile dysfunction and its interaction with the 
      cardiovascular system.
PG  - 53-64
LID - 10.1177/1074248413504034 [doi]
AB  - Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, 
      having numerous effects and functions. The PDE type 5 (PDE5) inhibitors are 
      widely used to treat erectile dysfunction (ED). Recent, intense preclinical and 
      clinical research with PDE5 inhibitors has shed light on new mechanisms and has 
      revealed a number of pleiotropic effects on the cardiovascular (CV) system. To 
      date, PDE5 inhibition has been shown to be effective for the treatment of 
      idiopathic pulmonary arterial hypertension, and both sildenafil and tadalafil are 
      approved for this indication. However, current or future PDE5 inhibitors have the 
      potential of becoming clinically useful in a variety of CV conditions such as 
      heart failure, coronary artery disease, and hypertension. The present review 
      discusses recent findings regarding pharmacologic treatment of ED and its 
      interaction with the CV system and highlights current and future clinical 
      applications beyond ED.
FAU - Ioakeimidis, Nikolaos
AU  - Ioakeimidis N
AD  - 1First Department of Cardiology, Cardiovascular Diseases and Sexual Health Unit, 
      Athens Medical School, Hippokration Hospital, Athens, Greece.
FAU - Kostis, John B
AU  - Kostis JB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131125
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Carbolines)
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 742SXX0ICT (Tadalafil)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - EC 3.1.4.- (Phosphoric Diester Hydrolases)
SB  - IM
MH  - Animals
MH  - Carbolines/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/physiopathology
MH  - Cardiovascular System/drug effects/physiopathology
MH  - Erectile Dysfunction/*drug therapy/physiopathology
MH  - Familial Primary Pulmonary Hypertension
MH  - Humans
MH  - Hypertension, Pulmonary/drug therapy/physiopathology
MH  - Male
MH  - Phosphodiesterase 5 Inhibitors/pharmacology/*therapeutic use
MH  - Phosphoric Diester Hydrolases/drug effects/metabolism
MH  - Piperazines/pharmacology/therapeutic use
MH  - Purines/pharmacology/therapeutic use
MH  - Sildenafil Citrate
MH  - Sulfones/pharmacology/therapeutic use
MH  - Tadalafil
OTO - NOTNLM
OT  - PDE5 inhibitors
OT  - cardiovascular disease
OT  - erectile dysfunction
EDAT- 2013/11/28 06:00
MHDA- 2014/09/03 06:00
CRDT- 2013/11/28 06:00
PHST- 2013/11/28 06:00 [entrez]
PHST- 2013/11/28 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
AID - 1074248413504034 [pii]
AID - 10.1177/1074248413504034 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):53-64. doi: 10.1177/1074248413504034. 
      Epub 2013 Nov 25.